R&D News | pharmaphorum

News

GSK wagers $750m on Chimagen multiple myeloma therapy

GSK has continued a drive to bulk up its pipeline, taking global rights to a T-cell engager for multiple myeloma, developed by China's Chimagen Bio.

News

Chiesi fills permanent CEO role with Flagship's Khougazian

Chiesi has named Flagship's David Khougazian as its new permanent chief executive, following the departure of Giuseppe Accogli earlier this year.

News

WCLC: Lung cancer news from BioNTech, Akeso, and Roche

As the World Conference on Lung Cancer (WCLC) draws to a close, here are some late-breaking clinical trial data that made waves at the congress.

News

GSK showcases positive data with lung cancer drugs at WCLC

New data at WCLC26 could push GSK's ROS1+ NSCLC drug Jideytro into the first-line setting, while B7-H3-targeted ADC ris-rez extends survival in SCLC.

News

AZ's Etcamah falls short in first-line breast cancer trial

A week after getting FDA approval for frontline breast cancer treatment, AstraZeneca's Etcamah missed the mark in a trial aiming to expand its label.

News

Andy Plump to step down as Takeda's R&D chief

Andy Plump, credited with a 'soup-to-nuts' overhaul of Takeda's R&D in more than a decade of leadership at the division, has announced his retirement.

GSK wagers $750m on Chimagen multiple myeloma therapy

Chiesi fills permanent CEO role with Flagship's Khougazian

WCLC: Lung cancer news from BioNTech, Akeso, and Roche

GSK showcases positive data with lung cancer drugs at WCLC

AZ's Etcamah falls short in first-line breast cancer trial

Andy Plump to step down as Takeda's R&D chief

AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks